| Uveitis
Xipere vs Yutiq
Side-by-side clinical, coverage, and cost comparison for uveitis.Deep comparison between: Xipere vs Yutiq with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsYutiq has a higher rate of injection site reactions vs Xipere based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Yutiq but not Xipere, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Xipere
Yutiq
At A Glance
Suprachoroidal injection
Corticosteroid
Intravitreal injection
Single implant (36-month release)
Corticosteroid
Indications
- Macular retinal edema
- Uveitis
- Uveitis
Dosing
Macular retinal edema, Uveitis 4 mg (0.1 mL) administered as a suprachoroidal injection using the SCS Microinjector.
Uveitis Single intravitreal implant (0.18 mg fluocinolone acetonide) injected under aseptic conditions into the vitreous, optimally placed inferior to the optic disc and posterior to the equator (4 mm inferotemporal from the limbus); monitor for IOP elevation and endophthalmitis following injection.
Contraindications
- Active or suspected ocular or periocular infections, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases
- Known hypersensitivity to triamcinolone acetonide or any other components of this product
- Active or suspected ocular or periocular infections, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases
- Known hypersensitivity to any components of this product
Adverse Reactions
Most common (>=10%) Elevated intraocular pressure, eye pain
Most common (>=1%) Cataract, visual acuity reduced, macular edema, uveitis, conjunctival hemorrhage, eye pain, hypotony of eye, anterior chamber inflammation, dry eye, vitreous opacities, conjunctivitis, posterior capsule opacification, ocular hyperemia
Serious Cataract requiring surgery, elevated IOP with potential optic nerve damage and visual field defects, secondary ocular infection including herpes simplex, perforation of globe in patients with corneal or scleral thinning
Pharmacology
Triamcinolone acetonide is a synthetic glucocorticoid with immunosuppressive and anti-inflammatory activity; its primary mechanism of action is as a corticosteroid hormone receptor agonist.
Corticosteroid; fluocinolone acetonide inhibits inflammatory responses by blocking phospholipase A2 via lipocortin induction, thereby suppressing prostaglandin and leukotriene synthesis and inhibiting edema, leukocyte migration, capillary proliferation, and fibroblast proliferation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Xipere
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Yutiq
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Xipere
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Yutiq
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Xipere
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Yutiq
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Inherited Retinal Diseases - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$25/fillfill
Yutiq Copay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.